Mirena in Idiopathic Menorrhagia

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This is an open-label, uncontrolled, multi-centre observational study that analyses a follow-up of 1600 women with dysfunctional uterine bleeding (idiopathic menorrhagia) over a period of one year.The patients evaluated at four visits, beginning with the insertion visit and 3, 6 and 12 months after insertion.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01085487` - MiCo - Mirena or Conventional Medical Treatment for Menorrhagia	N/A

NCT number	NCT00868153
Study type	Observational
Source	Bayer
Contact
Status	Completed
Phase	N/A
Start date	August 2004
Completion date	November 2008

Mirena in Idiopathic Menorrhagia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms